| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/01/2007 | US7211395 Serum albumin conjugate for use in the transfer and delivery of therapeutic agent to target |
| 05/01/2007 | US7211283 Casing of a gelatin-free, water- based, set hydrocolloid gel that forms an enclosure, and at least one solid, liquid, soft or particulate center enclosed by the casing |
| 05/01/2007 | US7211276 Method for preventing ulceration or irritation of mucosa |
| 05/01/2007 | US7211261 Stable liquid formulations of botulinum toxin |
| 05/01/2007 | US7211253 Erythropoietin forms with improved properties |
| 05/01/2007 | US7211251 Antibodies to transferrin receptor-like proteins |
| 05/01/2007 | US7211250 Method and composition for inhibiting cancer cell growth |
| 05/01/2007 | US7211248 Controlling lipid metabolism; injecting a solution of Dna, Rna gene using gas microbubbles using ultrasonic frequency; gene expression |
| 05/01/2007 | US7211240 Multivalent constructs for therapeutic and diagnostic applications |
| 05/01/2007 | US7211108 Can serve as a carrier for a very broad range of drugs, possibly including every drug presently used, being considered for use, or likely to be used in the future to inhibit stenosis |
| 05/01/2007 | CA2431397C Self emulsifying lipid matrix (selm) |
| 05/01/2007 | CA2366679C Stabilized oral pharmaceutical composition containing iodide and iodate and method |
| 05/01/2007 | CA2326756C Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
| 05/01/2007 | CA2254060C Effervescent bisphosphonate formulation |
| 05/01/2007 | CA2249637C Uniform drug delivery therapy |
| 05/01/2007 | CA2244357C A novel pharmaceutical composition for inhalation containing cr 2039 (andolast) |
| 05/01/2007 | CA2234585C Prolonged release of gm-csf |
| 05/01/2007 | CA2214343C Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate |
| 04/30/2007 | CA2554874A1 Methods of reducing alcohol-induced dose dumping for hydromorphone sustained release oral dosage forms |
| 04/30/2007 | CA2554701A1 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
| 04/30/2007 | CA2554698A1 Methods of reducing alcohol-induced dose dumping for hydrocodone sustained release oral dosage forms |
| 04/30/2007 | CA2554697A1 Methods of reducing alcohol-induced dose dumping for morphine sustained release oral dosage forms |
| 04/30/2007 | CA2554693A1 Methods of reducing alcohol-induced dose dumping for oxymorphone sustained release oral dosage forms |
| 04/30/2007 | CA2554684A1 Methods of reducing alcohol-induced dose dumping for oxycodone sustained release oral dosage forms |
| 04/26/2007 | WO2007046544A1 Preparation for external application comprising salt of mast cell degranulation inhibitor having carboxyl group with organic amine |
| 04/26/2007 | WO2007046538A1 Method for ubiquitination of consensus subunit in rna polymerases |
| 04/26/2007 | WO2007046411A1 Method for stabilization of isoxazole compound |
| 04/26/2007 | WO2007046356A1 Carrier composition for nucleic acid transport |
| 04/26/2007 | WO2007046318A1 Liquid preparation for external application containing indomethacin |
| 04/26/2007 | WO2007046315A1 External preparation for skin |
| 04/26/2007 | WO2007045469A1 Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| 04/26/2007 | WO2007045010A1 Inhibitory compounds |
| 04/26/2007 | WO2007027941A3 Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| 04/26/2007 | WO2007027819A3 Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| 04/26/2007 | WO2007022813A3 A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN |
| 04/26/2007 | WO2007012857A8 Topical formulations containing sporopollenin |
| 04/26/2007 | WO2007011764A3 Drospirenone containing transdermal drug delivery devices and methods of delivery thereof |
| 04/26/2007 | WO2007007014A3 Novel method for preparing chitin nanoparticles |
| 04/26/2007 | WO2007000671A3 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
| 04/26/2007 | WO2006133048A3 Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
| 04/26/2007 | WO2006121422A8 Antibodies against clostridium difficile toxins and uses thereof |
| 04/26/2007 | WO2006074451A9 Targeted chimeric molecules for cancer therapy |
| 04/26/2007 | WO2006067173A3 Antithrombotic dual inhibitors comprising a biotin residue |
| 04/26/2007 | WO2006050930A3 Conjugates with enhanced cell uptake activity |
| 04/26/2007 | WO2006042724A3 Magnetic particles for therapy and diagnosis |
| 04/26/2007 | WO2005041859A3 Conjugates and compositions for cellular delivery. |
| 04/26/2007 | WO2005035441A3 Subtituted fullerene compositions and their use as antioxydants |
| 04/26/2007 | US20070093645 Peptide vectors |
| 04/26/2007 | US20070093451 Compositions of estrogen-cyclodextrin complexes |
| 04/26/2007 | US20070093441 useful to efficiently induce self-specific immune responses; comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin |
| 04/26/2007 | US20070093417 Novel GLP-1 analogues linked to albumin-like agents |
| 04/26/2007 | US20070093405 Use of a solution comprising at least one nonionic surfactant |
| 04/26/2007 | US20070092582 Methods of preserving ophthalmic solutions and preserved ophthalmic solutions |
| 04/26/2007 | US20070092566 Oral sustained-release tablet |
| 04/26/2007 | US20070092564 comprising a drug and a matrix, wherein the matrix contains an amino acid and pullulan and the ratio by weight of the amino acid to pullulan is 0.1 to 10, wherein the amino acid is selected from glycine, serine, arginine and a combination thereof; disintegrates rapidly in mouth |
| 04/26/2007 | US20070092551 Therapeutic agent |
| 04/26/2007 | US20070092540 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof |
| 04/26/2007 | US20070092535 Delivery of drugs to mucosal surfaces |
| 04/26/2007 | US20070092526 Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
| 04/26/2007 | US20070092489 Use of receptor sequences for immobilizing gene vectors on surfaces |
| 04/26/2007 | US20070092487 use of a closure means coated by an inert fluorinated material (TEFLON) for a container of a liquid pharmaceutical composition ready for injection and containing a protein as active ingredient (interferon); human (HSA) serum albumins free |
| 04/26/2007 | US20070092466 in combination with carrier, and optionally activity enhancer; arresting or reversing hair loss, or both, and promoting hair growth; also a mascara; thickening and darkening hair |
| 04/26/2007 | US20070092444 Inhibition of inward sodium currents in cancer |
| 04/26/2007 | DE4332436B4 Cyclosporin enthaltende pharmazeutische Zusammensetzungen The cyclosporin-containing pharmaceutical compositions |
| 04/26/2007 | DE102005051366A1 Drug Delivery Systeme Drug Delivery Systems |
| 04/26/2007 | DE102005050895A1 Polyelectrolyte complex, useful for the production of stable medicinal forms, comprises chitosan polymer and carrageenan in a specific ratio |
| 04/26/2007 | CA2626357A1 Intranasal administration of rapid acting insulin |
| 04/26/2007 | CA2626305A1 Method of acting upon organism by targeted delivery of biologicaly active substances into m itochondria, pharmaceutical composition for carrying out said method, and compound usedfor the purpose |
| 04/26/2007 | CA2624840A1 Carrier composition for nucleic acid transport |
| 04/26/2007 | CA2624617A1 Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| 04/26/2007 | CA2557369A1 Liquid, peg-free, cold-processable oil-in-water emulsifiers obtainable by combining emulsifiers based on polyol partial esters and acid partial esters |
| 04/25/2007 | EP1777231A2 Process of purication of LH and recominant hLH purified by that method |
| 04/25/2007 | EP1776963A1 Hexosylceramides as adjuvants and their uses in pharmaceutical compositions |
| 04/25/2007 | EP1776953A1 Solid oral dosage forms comprising valsartan |
| 04/25/2007 | EP1776950A1 Opioid formulations for treating pain |
| 04/25/2007 | EP1776948A1 Method of producing liposome-containing preparation |
| 04/25/2007 | EP1776381A1 Toxin compounds with enhanced membrane translocation characteristics |
| 04/25/2007 | EP1776144A2 Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
| 04/25/2007 | EP1776143A1 Bifunctional derivatives of polyethylene glycol, their preparation and use |
| 04/25/2007 | EP1776135A1 Ejection liquid, ejection device, ejection cartridge, and method of making droplets from liquid |
| 04/25/2007 | EP1776132A2 Natriuretic compounds, conjugates, and uses thereof |
| 04/25/2007 | EP1776102A1 Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation |
| 04/25/2007 | EP1776093A1 Compositions containing nicorandil, preparation method and use |
| 04/25/2007 | EP1776090A1 Stabilised prostaglandin composition |
| 04/25/2007 | EP1536845B1 Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| 04/25/2007 | EP1421120B1 Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander |
| 04/25/2007 | EP1372777A4 Embolic devices capable of in-situ reinforcement |
| 04/25/2007 | EP1345982B1 Synthesis of high molecular weight non-peptidic polymer derivatives |
| 04/25/2007 | EP1292326B1 Use of inactive cln2 proenzyme for treating lincl |
| 04/25/2007 | EP1259813B1 Diagnosis of malignant neoplasms |
| 04/25/2007 | EP1197208B1 Sustained release compositions, process for producing the same and use thereof |
| 04/25/2007 | EP1194125B1 Method for making granules with masked taste and instant release of the active agent |
| 04/25/2007 | EP1049468B1 Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| 04/25/2007 | EP0995435B1 Aqueous suspension preparations with excellent redispersibility |
| 04/25/2007 | EP0934077B1 Polyanionic polymers as adjuvants for mucosal immunization |
| 04/25/2007 | EP0925358B1 Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use |
| 04/25/2007 | CN1954073A Modified Bouganin proteins, cytotoxins and methods and uses thereof |
| 04/25/2007 | CN1953769A Dietary supplement and method for treating digestive system-related disorders |
| 04/25/2007 | CN1953758A 活性发泡体 Active foam |
| 04/25/2007 | CN1953757A Composition for cleaning intestinal canal |